Neurogene's (NGNE) "Outperform" Rating Reiterated at William Blair

Neurogene (NASDAQ:NGNE - Get Free Report)'s stock had its "outperform" rating reissued by equities researchers at William Blair in a report issued on Tuesday,RTT News reports. William Blair also issued estimates for Neurogene's Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($3.70) EPS, Q1 2026 earnings at ($1.18) EPS, Q2 2026 earnings at ($1.11) EPS, Q3 2026 earnings at ($1.14) EPS, Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($4.60) EPS.

Separately, HC Wainwright dropped their price target on shares of Neurogene from $55.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $59.80.

Neurogene Stock Down 5.3 %

NASDAQ:NGNE traded down $0.81 on Tuesday, hitting $14.52. The stock had a trading volume of 98,611 shares, compared to its average volume of 210,041. Neurogene has a 52 week low of $13.47 and a 52 week high of $74.49. The business's fifty day moving average is $16.88 and its 200 day moving average is $28.82. The company has a market cap of $215.69 million, a PE ratio of -3.40 and a beta of 1.01.

Remove Ads

Neurogene (NASDAQ:NGNE - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.05. The business had revenue of $0.93 million for the quarter. Equities analysts predict that Neurogene will post -4.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of Neurogene stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $16.94, for a total transaction of $76,246.94. Following the sale, the chief financial officer now directly owns 72,343 shares in the company, valued at approximately $1,225,490.42. This trade represents a 5.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 9.92% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neurogene

Several large investors have recently made changes to their positions in the business. Samsara BioCapital LLC grew its position in Neurogene by 35.4% during the fourth quarter. Samsara BioCapital LLC now owns 1,717,127 shares of the company's stock valued at $39,254,000 after buying an additional 449,337 shares during the period. RTW Investments LP lifted its stake in Neurogene by 18.9% in the fourth quarter. RTW Investments LP now owns 1,350,256 shares of the company's stock valued at $30,867,000 after purchasing an additional 215,000 shares during the last quarter. Redmile Group LLC grew its holdings in Neurogene by 36.9% during the fourth quarter. Redmile Group LLC now owns 1,319,763 shares of the company's stock valued at $30,170,000 after purchasing an additional 355,416 shares during the period. Casdin Capital LLC increased its position in Neurogene by 146.9% in the fourth quarter. Casdin Capital LLC now owns 1,295,361 shares of the company's stock worth $29,612,000 after buying an additional 770,745 shares during the last quarter. Finally, FMR LLC raised its stake in shares of Neurogene by 912.4% in the third quarter. FMR LLC now owns 731,801 shares of the company's stock valued at $30,706,000 after buying an additional 659,515 shares during the period. 52.37% of the stock is owned by hedge funds and other institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.